CA2866037C — Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Assigned to Siga Technologies Inc · Expires 2017-05-16 · 9y expired
What this patent protects
The present invention relates to a process for producing 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide (ST-246) from a mixture of anti-tricyclo[3.2.2.0]non-6-ene-endo-8,endo-9-dicarboxylic acid anhydride, 4-(triflu…
USPTO Abstract
The present invention relates to a process for producing 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide (ST-246) from a mixture of anti-tricyclo[3.2.2.0]non-6-ene-endo-8,endo-9-dicarboxylic acid anhydride, 4-(trifluoromethyl)-benzhydrazide, and ethanol.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.